Zenith Capital (Zenith Capital) Capex-to-Operating-Income : 0.00 (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Zenith Capital's Capital Expenditure for the three months ended in . 20 was $0.00 Mil. Its Operating Income for the three months ended in . 20 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Zenith Capital Capex-to-Operating-Income Historical Data

The historical data trend for Zenith Capital's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Capex-to-Operating-Income Chart

Zenith Capital Annual Data

Trend

Capex-to-Operating-Income

Zenith Capital Quarterly Data

Capex-to-Operating-Income

Competitive Comparison of Zenith Capital's Capex-to-Operating-Income

For the Biotechnology subindustry, Zenith Capital's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Capex-to-Operating-Income falls into.

Zenith Capital Capex-to-Operating-Income Calculation

Zenith Capital's Capex-to-Operating-Income for the fiscal year that ended in . 20 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- ()	/
	=	N/A

Zenith Capital's Capex-to-Operating-Income for the quarter that ended in . 20 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- ()	/
	=	N/A

Zenith Capital (OTCPK:ZHCLF) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Zenith Capital Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines